

Editor-in-Chief
World Journal of Clinical Infectious Diseases

I would like to thank you for considering my manuscript, entitled “The Association between Pneumonia and Heart failure” for publication in World Journal of Clinical Infectious Diseases. As requested, I have revised the manuscript according to the comments made by the reviewer. Below are my responses (in red) to all of the questions posed by the reviewer.

This is a meaningful review on the clinical efficacy and safety of antibiotics for the treatment of complicated urinary tract infection and pyelonephritis, with scoping efforts ceftazidime-avibactam, doripenem, levofloxacin, meropenem-vaborbactam, piperacillin-tazobactam, plazomicin, tazobactam-ceftolozane and gentamicin. Authors suggest use of novel antibiotics and combination antibiotic therapy for treating complicated UTI and acute pyelonephritis when resistance to recommended antibiotics occurs. This is a comprehensive review and I have only minor comments that could help Abstract - I believe the use of English needs improving here Authors should define IDSA and ESCMID when first used On methods, authors should again mention that PRISMA protocol was used. Who reviewed the papers? Please describe on “Selection of studies and analyses” I liked the results section however I would like to see a flowchart showing the eligibility/rejections, with reasons why. This helps in seeing the construction of the review

Thank you the review.

1. The abstract has been revised and reviewed for clarity by a native English-speaker colleague.
2. The terms IDSA and ESCMID have been defined.
3. PRIMSA protocol have been mentioned on the “Selection of studies and analyses” section.
4. The author who reviewed the papers for quality have been mentioned on the “Selection of studies and analyses” section.
5. Flow diagram of the study selection process showing rejections with reasons have been shown in Figure 1.